

## CLAIM LISTING

1. (Cancelled)
2. (Cancelled)
3. (Cancelled)
4. (Cancelled)
5. (Cancelled)
6. (Previously presented) A pharmaceutical composition comprising 5-[[4-[13-Methyl]-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenyl-methyl]thiazolidine-2,4-dione or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable excipients with low water content comprising anhydrous lactose, microcrystalline cellulose, magnesium stearate, and talc..
7. (Original) The pharmaceutical composition according to claim 6 in the form of a tablet, a powder or a capsule.
8. (Cancelled)
9. (Previously presented) The pharmaceutical composition according to claim 6 wherein the pharmaceutically acceptable excipients are between 100 and 400,000 parts by weight of anhydrous lactose, between 1000 and 10,000 parts by weight of microcrystalline cellulose, and between 10 and 500 parts by weight of magnesium stearate, expressed in parts by weight per 100 parts of 5-[[4-[3-Methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenyl-methyl]thiazolidine-2,4-dione, or of one of its pharmaceutically acceptable salts.

10. (Cancelled)
11. (Previously presented) The pharmaceutical composition according to claim 6 wherein the pharmaceutically acceptable excipients have a low water content.
12. (Previously presented) The pharmaceutical composition according to claim 6 wherein the pharmaceutically acceptable excipients have a very low water content.
13. (Previously presented) The pharmaceutical composition according to claim 6 wherein the pharmaceutically acceptable excipients are in a dry form.
14. (Cancelled)
15. (Cancelled)
16. (Previously presented) The pharmaceutical composition according to claim 6, further comprising at least one sweetener, flavouring agent, colour or lubricant.
17. (Cancelled)
18. (Cancelled)
19. (Cancelled)
20. (Cancelled)
21. (Cancelled)

22. (Cancelled)

23. (Cancelled)

24. (Cancelled)

25. (Cancelled)

26. (Cancelled)

27. (Cancelled)

28. (Previously presented) The pharmaceutical composition according to claim 6 in tablet form, wherein the tablet is formed by direct compression.

29. (Previously presented) The pharmaceutical composition according to claim 6 consisting of 5-[[4-[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenyl methyl] thiazolidine-2,4-dione or a pharmaceutically acceptable salt thereof

	9%
Microcrystalline cellulose	20%
Anhydrous lactose	66%
Magnesium Stearate	0.5%
Talc	4.5%

30. (Previously presented) The pharmaceutical composition according to claim 29 in the form of a tablet, a powder or a capsule.

31. (Previously presented) The pharmaceutical composition according to claim 30 in tablet form, wherein the tablet is formed by direct compression.